About Fluxion Biosciences
Fluxion Biosciences is a company based in San Francisco (United States) founded in 2005 was acquired by Cell Microsystems in August 2023. Fluxion Biosciences has raised $20.85 million across 9 funding rounds from investors including NIH, HHS and National Cancer Institute. Fluxion Biosciences offers products and services including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder. Fluxion Biosciences operates in a competitive market with competitors including Guardant Health, GRAIL, MaxCyte, Thrive Earlier Detection and SQZBiotech, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.85 M (USD)
in 9 rounds
-
Latest Funding Round
Not available
-
Investors
NIH
& 8 more
-
Employee Count
Not available
-
Acquired by
Cell Microsystems
(Aug 23, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fluxion Biosciences
Fluxion Biosciences offers a comprehensive portfolio of products and services, including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder.
Platform for isolating and growing single cells efficiently.
Enables physiological shear flow for drug discovery experiments.
Supports 3D cell culture for organoid and tissue research.
Offers accurate counting and viability assessment of cells.
Facilitates fast, enzyme-free tissue dissociation for analysis.
People of Fluxion Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Fluxion Biosciences
Fluxion Biosciences has successfully raised a total of $20.85M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fluxion Biosciences
Fluxion Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early stage venture fund investing in North America and Canada
|
Locked | Locked | Locked | |
|
PE firm investing in North America and Europe
|
Locked | Locked | Locked | |
|
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries.
|
Locked | Locked | Locked |
Investor details for Fluxion Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fluxion Biosciences
Investment portfolio details for Fluxion Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fluxion Biosciences
Detailed financials for Fluxion Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fluxion Biosciences Comparisons
Peer comparison for Fluxion Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fluxion Biosciences
Fluxion Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, MaxCyte, Thrive Earlier Detection and SQZBiotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Instrument systems for cell processing and modification are provided.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Cell therapies are developed using proprietary Cell Squeeze technology.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
Detailed competitors of Fluxion Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fluxion Biosciences
Complete news archive for Fluxion Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fluxion Biosciences
Fluxion Biosciences was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Fluxion Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fluxion Biosciences is a funded company, having raised a total of $20.85M across 9 funding rounds to date.
Provider of microfluidics-based tools for cellular analysis. It has three main systems which inlcude the IsoFlux Liquid biopsy system uses next-gen sequencing (NGS) to detect somatic variants from circulating tumor cells (CTCs) in blood. Fluxion also provides the reagent kits necessary for analysis with the IsoFlux system. The BioFlux system is a flow-through system that allows researchers to emulate in vivo shear flow conditions during drug discovery. The IonFlux system uses microfluidic technology for automated patch clamping. This system can be used to perform ligand binding, allosteric modulation, multiple agonists, and voltage- and temperature-sensitive assays for ion channel screening in drug discovery.
Fluxion Biosciences's top competitors include Guardant Health, GRAIL and MaxCyte.
Fluxion Biosciences offers CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder.
Fluxion Biosciences has 9 investors. Key investors include NIH, HHS, National Cancer Institute, Cell Microsystems, and NICHD.